Nova Mentis Life Science Corp. NMLSF
We take great care to ensure that the data presented and summarized in this overview for Nova Mentis Life Science Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in NMLSF
Top Purchases
Top Sells
About NMLSF
Nova Mentis Life Science Corp., through its subsidiaries, engages in developing diagnostics and psilocybin based therapeutics for neuroinflammatory conditions with a focus on autism spectrum disorder and fragile X syndrome in Canada. It is also involved in the research and development of anti-inflammatory effects of psilocybin for metabolic indications, such as obesity and diabetes; and development of cannabis products. Nova Mentis Life Science Corp. has a research agreement with the University of Central Florida (UCF) to develop a saliva serotonin assay. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is headquartered in Vancouver, Canada.
Insider Transactions at NMLSF
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|